Johnson & Johnson $JNJ Stock Bought by Allspring Global Investments Holdings LLC

Key Points

• Allspring Global Investments increased its Johnson & Johnson stake by 5.7% in the third quarter, adding 38,654 shares to hold 712,721 shares valued at about $184.4 million. Institutional investors own 69.55% of the company.
• J&J’s Innovative Medicine sales rose 7.7% to $16.76 billion in the third quarter, while overall revenue increased 5.9% year over year to $25.4 billion and adjusted earnings beat analysts’ estimates.
• The FDA granted accelerated approval to RYBREVANT FASPRO for certain patients with recurrent or metastatic head and neck cancer, expanding the drug’s potential use beyond lung cancer. J&J also declared a quarterly dividend of $1.34 per share.

Allspring Global Investments Holdings LLC increased its position in Johnson & Johnson (NYSE:JNJ - Free Report) by 5.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 712,721 shares of the company's stock after buying an additional 38,654 shares during the period. Allspring Global Investments Holdings LLC's holdings in Johnson & Johnson were worth $184,352,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Mizuho Securities Co. Ltd. bought a new stake in Johnson & Johnson in the 3rd quarter worth about $79,000. Griffith & Werner Inc. increased its stake in Johnson & Johnson by 5.7% in the 3rd quarter. Griffith & Werner Inc. now owns 26,244 shares of the company's stock valued at $6,948,000 after buying an additional 1,411 shares during the last quarter. Burton Enright Welch increased its stake in Johnson & Johnson by 17.7% in the 3rd quarter. Burton Enright Welch now owns 4,140 shares of the company's stock valued at $1,096,000 after buying an additional 622 shares during the last quarter. Beverly Hills Private Wealth LLC lifted its position in shares of Johnson & Johnson by 4.2% during the 3rd quarter. Beverly Hills Private Wealth LLC now owns 14,822 shares of the company's stock worth $3,924,000 after buying an additional 597 shares in the last quarter. Finally, Brickley Wealth Management lifted its position in shares of Johnson & Johnson by 3.2% during the 3rd quarter. Brickley Wealth Management now owns 1,448 shares of the company's stock worth $383,000 after buying an additional 45 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Key Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

Insider Activity

In related news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. This trade represents a 56.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Jennifer Taubert sold 15,000 shares of the business's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the sale, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. This represents a 7.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Down 0.0%

Johnson & Johnson stock opened at $276.14 on Monday. The firm has a 50 day moving average price of $265.91 and a 200-day moving average price of $248.30. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. Johnson & Johnson has a twelve month low of $185.12 and a twelve month high of $282.02. The company has a market capitalization of $664.76 billion, a P/E ratio of 41.84, a P/E/G ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company had revenue of $25.40 billion for the quarter, compared to analysts' expectations of $25.38 billion. During the same quarter in the previous year, the firm posted $2.80 EPS. Johnson & Johnson's revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities analysts predict that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson's dividend payout ratio (DPR) is 81.21%.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Erste Group Bank downgraded Johnson & Johnson from a "buy" rating to a "hold" rating in a research note on Wednesday, October 21st. The Goldman Sachs Group reaffirmed a "buy" rating and set a $282.00 price target on shares of Johnson & Johnson in a research report on Thursday, July 16th. Royal Bank Of Canada dropped their price target on Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating on the stock in a report on Wednesday, October 14th. Leerink Partners dropped their price target on Johnson & Johnson from $276.00 to $272.00 and set an "outperform" rating on the stock in a report on Wednesday, October 14th. Finally, Citigroup boosted their price objective on Johnson & Johnson from $298.00 to $303.00 and gave the stock a "buy" rating in a research report on Monday, October 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $275.92.

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.